- Select Medical ( NYSE: SEM ) is trading down 9% premarket after the company reported Q2 GAAP EPS that were below estimates.
- The company said it expects its full-year forecast to be in the range of $6.25B to $6.40B, the mid-point was below analysts estimate of $638B.
- The company posted Q2 GAAP EPS of $0.43m which missed estimates by $0.11, while revenue rose 1.3% Y/Y to $1.58B and was in-line with estimates.
- Select Medical also reaffirmed its previously issued three-year compound annual growth rate target for revenue only, which is expected to be in the range of 4% to 6% for 2021 through 2023.
- Critical Illness Recovery Hospital Segment rose only 0.3% Y/Y to $545.9M. Patient admission in critical illness hospital fell 2.4%.
- Concentra Segment fell 3.3% Y/Y to $441.4.
For further details see:
Select Medical down 9% on Q2 profit miss, reiterates full-year forecast